Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematopoietic Neoplasm: full-pipeline trial registry
1 of 4 indexed Hematopoietic Neoplasm trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hematopoietic Neoplasm: 4 US clinical trials tracked, 1 recruiting.
Hematopoietic Neoplasm is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 2 of these trials.
Enrollment posture brief
Registry condition hematopoietic-neoplasm
OPEN 1 | RECR 25% | LATE 1 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Hematopoietic Neoplasm lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematopoietic Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematopoietic Neoplasm is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Wearable Activity Tracking to Curb Hospitalizations
University of California, San Francisco
NCT06587100
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Bristol-Myers Squibb
NCT01437787
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Bristol-Myers Squibb
NCT01420770
Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors
Wake Forest University Health Sciences
NCT06881108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematopoietic Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematopoietic Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematopoietic Neoplasm page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hematopoietic Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Hematopoietic Neoplasm trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematopoietic Neoplasm condition card totals 4 registered trials; most-linked intervention SAR302503; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.